B12 Deficiency Anemia (20-page

Cheatsheet Content

### 1. Introduction to Vitamin B12 Deficiency Anemia Vitamin B12 (cobalamin) deficiency is a multifaceted disorder affecting various organ systems, prominently the hematopoietic and neurological systems. Its spectrum ranges from subclinical states to severe, life-threatening complications. This cheatsheet aims to provide a comprehensive, hematologist-level overview of B12 deficiency anemia. #### 1.1 Chemical Properties of Cobalamin - **Structure:** Complex organometallic compound with a corrin ring coordinating a central cobalt atom. - **Biologically Active Forms:** - **Methylcobalamin:** Acts as a cofactor for methionine synthase, essential for folate metabolism and DNA synthesis. - **5'-Deoxyadenosylcobalamin:** Cofactor for methylmalonyl-CoA mutase, involved in odd-chain fatty acid and branched-chain amino acid catabolism. - **Sources:** Primarily animal products (meat, fish, eggs, dairy). Synthesized by microorganisms. ### 2. Cobalamin Metabolism and Absorption A complex multi-step process ensuring efficient uptake and transport. #### 2.1 Gastric Phase 1. **Release:** Dietary B12 is released from food proteins by gastric acid and pepsin. 2. **R-binder binding:** B12 rapidly binds to R-binders (haptocorrins, transcobalamin I), glycoproteins secreted by salivary glands and gastric mucosa. This complex protects B12 from degradation in the acidic stomach. #### 2.2 Duodenal Phase 1. **R-binder degradation:** Pancreatic proteases (trypsin) degrade R-binders, releasing B12. 2. **Intrinsic Factor (IF) binding:** Free B12 then binds to intrinsic factor, a glycoprotein secreted by gastric parietal cells. The IF-B12 complex is critical for ileal absorption. #### 2.3 Ileal Phase 1. **Receptor-mediated endocytosis:** The IF-B12 complex travels to the terminal ileum and binds to specific receptors (cubilin and megalin, part of the cubam complex) on enterocytes. 2. **Internalization:** The complex is internalized via endocytosis. Within the enterocyte, IF is degraded, and B12 is released. #### 2.4 Plasma Transport 1. **Transcobalamin II (TCII) binding:** B12 is immediately bound to transcobalamin II (TCII), a plasma protein (beta-globulin) synthesized in the liver and kidneys. 2. **Distribution:** The TCII-B12 complex (holotranscobalamin, or holoTC) is the metabolically active form of B12, delivering it to all rapidly dividing cells, including hematopoietic cells, via specific TCII receptors. 3. **Other Transcobalamins:** TC I and TC III primarily function as storage and scavenger proteins, binding inactive B12 analogues. HoloTC constitutes only 10-30% of total plasma B12 but represents the bioavailable fraction. ### 3. Etiology and Pathophysiology Deficiency arises from impaired absorption, inadequate intake, or increased demand. #### 3.1 Impaired Absorption (Most Common Cause) - **Pernicious Anemia (PA):** Autoimmune destruction of gastric parietal cells leading to intrinsic factor deficiency. Accounts for 80-90% of adult B12 deficiency. - Associated with other autoimmune diseases (e.g., Hashimoto's thyroiditis, type 1 diabetes). - **Gastric Causes:** - **Gastrectomy:** Partial or total removal of stomach eliminates IF production. - **Achlorhydria/Hypochlorhydria:** Reduced gastric acid impairs B12 release from food. Can be due to: - Atrophic gastritis (non-autoimmune). - H2 blockers, proton pump inhibitors (PPIs) used long-term. - **Bariatric surgery:** Especially Roux-en-Y gastric bypass. - **Pancreatic Insufficiency:** Reduced pancreatic protease secretion impairs R-binder degradation (e.g., chronic pancreatitis, cystic fibrosis). - **Terminal Ileal Disease:** Impairment of cubam receptor function or destruction of enterocytes. - Crohn's disease affecting the ileum. - Ileal resection. - Celiac disease (severe, refractory cases). - **Bacterial Overgrowth (SIBO):** Bacteria in the small intestine compete with the host for B12, or degrade the IF-B12 complex. - Blind loop syndrome. - Diverticulosis of small bowel. - **Parasitic Infestation:** *Diphyllobothrium latum* (fish tapeworm) consumes B12. #### 3.2 Inadequate Dietary Intake - **Strict Vegetarians/Vegans:** Prolonged absence of animal products without supplementation. Less common in developed countries due to fortified foods. - **Malnutrition/Famine:** Globally, a significant but often overlooked cause. #### 3.3 Increased Demand/Loss - **Pregnancy/Lactation:** Increased fetal/infant demand. - **Generalized Malabsorption Syndromes:** Tropical sprue. - **Rare Genetic Disorders:** - **Imerslund-Gräsbeck Syndrome:** Autosomal recessive disorder affecting cubilin/megalin receptors. - **Transcobalamin II Deficiency:** Leads to impaired intracellular B12 transport and severe early-onset megaloblastic anemia. - **Methylmalonic aciduria and homocystinuria:** Defects in B12 metabolic enzymes. #### 3.4 Drug-Induced Deficiency - **Metformin:** Reduces ileal absorption of B12, possibly by interfering with calcium-dependent IF-B12 binding or motility. - **Nitrous Oxide (N2O):** Inactivates methylcobalamin by oxidizing the cobalt atom, irreversibly inhibiting methionine synthase. Can precipitate or worsen deficiency, especially in individuals with subclinical deficiency. - **Proton Pump Inhibitors (PPIs) and H2 Receptor Blockers:** Prolonged use reduces gastric acid, impairing B12 release from food proteins. - **Colchicine, Neomycin, Cholestyramine:** Can interfere with ileal absorption. ### 4. Clinical Manifestations Clinical presentation is highly variable and depends on severity and duration of deficiency. Affects bone marrow, GI tract, and nervous system primarily. #### 4.1 Hematologic Manifestations - **Megaloblastic Anemia (Macrocytic Anemia):** - **Pathophysiology:** Impaired DNA synthesis due to methylcobalamin deficiency leads to delayed nuclear maturation relative to cytoplasmic maturation in hematopoietic precursors. This results in large, immature cells. - **Peripheral Blood Smear:** - **Macrocytic, normochromic RBCs:** MCV > 100 fL (often > 110 fL). - **Anisocytosis and Poikilocytosis:** Significant variation in RBC size and shape. - **Oval macrocytes (macro-ovalocytes):** Characteristic. - **Hypersegmented neutrophils:** >5 lobes, typically 5+ cells with 5+ lobes per 100 WBCs, or 1+ cell with 6+ lobes. Pathognomonic for megaloblastic anemia. - **Basophilic stippling:** May be present. - **Pancytopenia:** Common, affecting all three lineages: - **Leukopenia/Neutropenia:** Often with relative lymphocytosis. - **Thrombocytopenia:** Abnormal giant platelets may be seen. - **Bone Marrow:** - **Hypercellular:** Marrow is usually hypercellular due to ineffective erythropoiesis. - **Megaloblastic changes:** Erythroid precursors show nuclear-cytoplasmic asynchrony (immature nucleus, mature cytoplasm leading to "blue-red" appearance). - **Giant metamyelocytes:** Large myeloid precursors. - **Increased iron stores:** Due to ineffective erythropoiesis (iron not incorporated into heme). - **Hemolysis:** Intramedullary and extramedullary hemolysis due to ineffective erythropoiesis. - Elevated indirect bilirubin, LDH. - Decreased haptoglobin. #### 4.2 Neurological Manifestations (Subacute Combined Degeneration) - **Pathophysiology:** Caused by impaired myelin synthesis and maintenance due to 5'-deoxyadenosylcobalamin deficiency, leading to demyelination and axonal degeneration. Can occur *independent* of anemia. - **Symptoms:** - **Sensory:** Paresthesias (tingling, numbness) in extremities (glove-and-stocking distribution), impaired proprioception (vibratory and position sense), sensory ataxia. - **Motor:** Weakness, spasticity, hyperreflexia, positive Babinski sign. - **Autonomic:** Orthostatic hypotension, erectile dysfunction, bladder dysfunction. - **Cognitive/Psychiatric:** Memory loss, subtle personality changes, depression, irritability, dementia, psychosis (megaloblastic madness). - **Progression:** Untreated, neurological damage can become irreversible. #### 4.3 Gastrointestinal Manifestations - **Glossitis:** "Beefy red," smooth, sore tongue (Hunter's glossitis). Atrophy of lingual papillae. - **Anorexia, weight loss, diarrhea/constipation.** - **Early satiety.** #### 4.4 Other Non-Specific Symptoms - Fatigue, weakness, pallor, shortness of breath, palpitations (anemia-related). - Jaundice (due to hemolysis). ### 5. Diagnosis A multi-faceted approach is essential for accurate diagnosis and identifying the underlying cause. #### 5.1 Initial Screening Tests - **Complete Blood Count (CBC):** - **Macrocytic anemia:** MCV > 100 fL. In some cases, MCV can be normal if co-existing iron deficiency or thalassemia trait is present. - **Pancytopenia:** Leucopenia/neutropenia, thrombocytopenia in severe cases. - **Peripheral Blood Smear:** Oval macrocytes, hypersegmented neutrophils are key findings. - **Reticulocyte Count:** Low (reflects ineffective erythropoiesis). #### 5.2 Specific B12 Markers - **Serum Vitamin B12 Level:** - **Normal Range:** Varies by lab, generally 200-900 pg/mL (148-664 pmol/L). - **Interpretation:** - ** 0.4 µmol/L). It rises earlier than B12 levels decline. - **Considerations:** Can be falsely elevated in renal insufficiency, hereditary MMA-urias. - **Homocysteine (Plasma):** - **Pathophysiology:** Methylcobalamin is a cofactor for methionine synthase, which converts homocysteine to methionine. Deficiency leads to accumulation of homocysteine. - **Utility:** Elevated homocysteine (often > 15 µmol/L) is indicative of B12 or folate deficiency. Non-specific without other markers. - **Considerations:** Can be elevated in renal insufficiency, folate deficiency, genetic enzyme defects, hypothyroidism. #### 5.3 Confirming the Etiology - **Anti-Intrinsic Factor Antibodies:** - **Utility:** Highly specific (approx. 95%), but less sensitive (approx. 50-70%) for pernicious anemia. Presence confirms PA. More useful as a confirmatory test. - **Type 1 (Blocking):** Prevents B12 binding to IF. - **Type 2 (Binding):** Prevents IF-B12 complex binding to ileal receptors. - **Anti-Parietal Cell Antibodies:** - **Utility:** Less specific (up to 10% of healthy individuals, and other gastric conditions), but more sensitive (approx. 90%) for PA. Useful as a screening test. - **Gastric Endoscopy with Biopsy:** - **When to consider:** If anti-IF antibodies are negative but PA is strongly suspected, or to rule out other gastric pathologies (e.g., autoimmune atrophic gastritis, gastric carcinoma). Biopsy may show atrophy and intestinal metaplasia. - **Schilling Test (Historical, Rarely Used):** - **Principle:** Measures absorption of radiolabeled B12, with and without exogenous IF. - **Phases:** 1. Oral radiolabeled B12 + parenteral non-labeled B12 (to saturate binding sites and allow excretion). Collect 24-hr urine. If low excretion, absorption defect. 2. If phase 1 abnormal, repeat with oral radiolabeled B12 + IF. If excretion normalizes, confirms IF deficiency (Pernicious Anemia). - **Limitations:** Difficult to perform, unavailable in many centers, replaced by antibody testing. - **Malabsorption workup:** Consider tests for H. pylori, SIBO (breath test), pancreatic function, celiac serology, small bowel imaging in cases not explained by PA or dietary deficiency. ### 6. Differential Diagnosis of Macrocytosis Not all macrocytosis is B12 deficiency. A thorough evaluation is needed. #### 6.1 Megaloblastic Anemias - **Folate Deficiency:** Clinically similar to B12 deficiency, but no neurological symptoms. Elevated homocysteine, normal MMA, low folate. - **Drug-induced:** Methotrexate, hydroxyurea, azathioprine, zidovudine, phenytoin (can cause folate deficiency). - **Myelodysplastic Syndromes (MDS):** Often macrocytic anemia, but typically with dysplastic features on blood smear and bone marrow. B12, folate, MMA levels are normal. Refractory anemia with ring sideroblasts (RARS) can be a subtype. - **Acute Myeloid Leukemia (AML):** M6 (erythroid leukemia) can present with striking megaloblastic changes. #### 6.2 Non-Megaloblastic Macrocytosis - **Alcoholism/Liver Disease:** Most common cause of non-megaloblastic macrocytosis. Direct toxic effect on erythropoiesis, folate deficiency (common in alcoholics), or changes in lipid composition of RBC membranes leading to target cells. - **Aplastic Anemia:** Marrow failure with pancytopenia and often macrocytosis. - **Hypothyroidism:** Can cause mild macrocytosis. - **Reticulocytosis:** High retic count can falsely elevate MCV as reticulocytes are larger than mature RBCs. Not a true macrocytosis. - **Multiple Myeloma/Plasma Cell Disorders:** Rarely, can cause macrocytosis. - **Artifactual (Cold Agglutinin Disease):** Severe cold agglutinins can cause RBC clumping, leading to a falsely elevated MCV (machine counts clumps as single large cells). ### 7. Treatment Replacement therapy is the cornerstone of treatment and must be lifelong for chronic malabsorption causes. #### 7.1 General Principles - **Identify and treat underlying cause:** Address reversible causes (e.g., SIBO, drug discontinuation). - **Correction of deficiency:** Parenteral or high-dose oral B12. - **Monitor response:** Hematologic and clinical improvement. #### 7.2 Parenteral Cobalamin (Intramuscular, IM) - **Commonly used forms:** Cyanocobalamin, Hydroxocobalamin (preferred in Europe, higher tissue retention). - **Initial Dosing (Severe deficiency, neurological symptoms, or non-compliance concerns):** - 1000 µg IM daily for 7-10 days. - Followed by 1000 µg IM weekly for 4-8 weeks. - Then, 1000 µg IM monthly for life (for pernicious anemia or irreversible malabsorption). - **Less severe deficiency (without neurological symptoms):** - 1000 µg IM weekly until correction of anemia, then monthly for maintenance. - **Advantages:** Ensures absorption regardless of GI tract integrity. Rapid response. - **Disadvantages:** Injections, potential discomfort. #### 7.3 Oral Cobalamin - **Dosing:** High-dose oral B12 (1000-2000 µg/day) can be effective even in pernicious anemia. - **Mechanism:** Pharmacological doses allow sufficient passive diffusion (1-2% of dose) across the intestinal mucosa, bypassing IF. - **Utility:** Recommended for patients with confirmed PA without severe neurological symptoms, and for dietary deficiency. - **Advantages:** Non-invasive, comparable efficacy to IM in many settings. - **Sublingual/Nasal Formulations:** Available but generally not superior to high-dose oral. #### 7.4 Special Considerations - **Potassium Replacement:** Rapid hematopoiesis can lead to hypokalemia. Monitor potassium levels in initial treatment phase, especially in severe anemia. - **Folate Co-administration:** If folate deficiency is concurrent, it must be corrected simultaneously. Replenishing B12 without adequate folate can precipitate or worsen folate deficiency. Folate should never be given alone in suspected B12 deficiency before B12 is confirmed or replaced, as it can alleviate anemia but allow neurological damage to progress. - **Neurological Symptoms:** Initiate treatment promptly. Neurological recovery is variable and depends on severity and duration of symptoms before treatment. Early intervention is crucial. Recovery may be incomplete. - **Pregnancy and Lactation:** Treat B12 deficiency aggressively to prevent infant neurological damage. Oral or IM therapy is safe. - **Metformin-induced deficiency:** High-dose oral B12 is usually sufficient while continuing metformin if needed. - **Nitrous Oxide Exposure:** Avoid repeat exposure. Supplement with B12. #### 7.5 Monitoring Treatment Response - **Hematologic:** - **Reticulocyte count peak:** Typically 5-10 days post-initiation of therapy ("reticulocyte crisis"). - **Hemoglobin increase:** Should be evident by 2 weeks, normalization by 4-8 weeks. - **MCV normalization:** Slower, may take up to 4-6 months as old macrocytes are replaced. - **Resolution of hypersegmented neutrophils.** - **Biochemical:** - **MMA and Homocysteine levels:** Should normalize within weeks to months. They are good markers of tissue B12 sufficiency. - **Serum B12:** Will rise rapidly with therapy. - **Clinical:** Resolution of anemia symptoms, improvement in neurological symptoms (slower, variable). ### 8. Prognosis and Complications #### 8.1 Prognosis - **Hematologic:** Excellent with appropriate and timely treatment. Anemia resolves completely. - **Neurological:** Partial to complete recovery depending on duration and severity. Earlier diagnosis and treatment lead to better outcomes. Long-standing or severe neurological damage may be irreversible. - **Pernicious Anemia:** Requires lifelong B12 replacement. #### 8.2 Complications - **Continued Neurological Damage:** If untreated or inadequately treated, leading to persistent or progressive ataxia, spasticity, cognitive decline. - **Cardiac Complications:** Severe, prolonged anemia can lead to high-output cardiac failure. - **Infertility:** Reversible with treatment. - **Increased Risk of Gastric Carcinoma:** In pernicious anemia, due to chronic atrophic gastritis and intestinal metaplasia. Regular endoscopic surveillance is often recommended. - **Increased Risk of Gastric Carcinoid Tumors:** Due to hypergastrinemia secondary to achlorhydria from parietal cell loss. ### 9. Future Directions and Research #### 9.1 Genetic Predisposition - Ongoing research into genetic factors predisposing to pernicious anemia and other B12 absorption disorders. - Pharmacogenomics: Understanding individual responses to B12 supplementation. #### 9.2 Advanced Diagnostics - Refinement of point-of-care B12 testing. - Development of novel biomarkers for early or subclinical deficiency. - Improved differentiation between B12 and folate deficiency in complex cases. #### 9.3 Therapeutic Innovations - More convenient B12 delivery methods (e.g., transdermal patches, enhanced oral absorption formulations). - Targeted therapies for specific genetic B12 metabolic disorders. - Strategies to mitigate metformin-induced deficiency. #### 9.4 Public Health - Addressing B12 deficiency in vulnerable populations (elderly, vegans, low-income countries). - Fortification of staple foods in at-risk regions. - Improved awareness among healthcare providers regarding neurological manifestations in absence of anemia.